Armata reports regulatory progress for AP-SA02 toward Phase 3
Armata submitted a Phase 3 protocol and FDA responses to advance its staphylococcus aureus therapy toward a pivotal 2026 trial, supported by DoD funding.
View filing at SEC.gov →3 most recent filings and news items mentioning ARMP. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/ARMP/news?limit=20"
Pull ARMP filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayArmata submitted a Phase 3 protocol and FDA responses to advance its staphylococcus aureus therapy toward a pivotal 2026 trial, supported by DoD funding.
View filing at SEC.gov →Armata Pharmaceuticals received FDA agreement on the Initial Pediatric Study Plan (iPSP) for AP-SA02 to treat resistant staph infections in children. This regulatory milestone advances the company toward a Biologics License Application for pediatric patients.
View filing at SEC.gov →Armata Pharmaceuticals announced receiving $2.5 million in non-dilutive funding from the Department of Defense to support clinical development of AP-SA02 for antibiotic-resistant infections. The award enhances the company's cash position and bolsters the path to regulatory approv
View filing at SEC.gov →